Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It

Ardelyx (NASDAQ: ARDX ) lost the lawsuit against Medicare, the one that I was worried about in my earlier article . With that loss, XPHOZAH faces the prospect of much reduced and declining revenue. ARDX has no other major prospectAbout the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. For ...